Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Immunoglobulin,Human Immunoglobulin
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Recipient : CSI Pharmacy
Deal Size : Undisclosed
Deal Type : Agreement
CSI Pharmacy Announces Limited Distribution Agreement for Gammaplex
Details : Under the agreement, CSI Pharmacy will get access for limited distribution rights to BPL's immune globulin product Gammaplex® (human immunoglobulin). Immune globulin products contain human antibodies, derived primarily from donated human plasma.
Product Name : Gammaplex
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
March 30, 2023
Lead Product(s) : Immunoglobulin,Human Immunoglobulin
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Recipient : CSI Pharmacy
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Coagulation Factor X (Human),Coagulation Factor X
Therapeutic Area : Hematology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
BPL Receives Orphan Drug Marketing Authorization for Coagadex® in Mexico
Details : Coagadex® is the first and only treatment specifically for Hereditary Factor X Deficiency, a very rare inherited clotting disorder that causes problems with blood clotting due to not having enough Factor X in the blood.
Product Name : Coagadex
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 04, 2022
Lead Product(s) : Coagulation Factor X (Human),Coagulation Factor X
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : HRIG
Therapeutic Area : Undisclosed
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Effectiveness of BPL HRIG With Active Rabies Vaccine in Healthy Subjects
Details : HRIG is a drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 29, 2017
Lead Product(s) : HRIG
Therapeutic Area : Undisclosed
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Factor IX
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Factor IX is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hemophilia B.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
October 13, 2014
Lead Product(s) : Factor IX
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Factor IX
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Factor IX is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hemophilia B.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
October 13, 2014
Lead Product(s) : Factor IX
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Factor IX
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Factor IX is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hemophilia B.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
September 26, 2014
Lead Product(s) : Factor IX
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Factor IX
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Factor IX is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hemophilia B.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
September 26, 2014
Lead Product(s) : Factor IX
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Optivate Human Coagulation Factor VIII
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Optivate Human Coagulation Factor VIII is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hemophilia A.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
September 26, 2014
Lead Product(s) : Optivate Human Coagulation Factor VIII
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Optivate Human Coagulation Factor VIII
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Optivate Human Coagulation Factor VIII is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of von Willebrand Diseases.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
September 26, 2014
Lead Product(s) : Optivate Human Coagulation Factor VIII
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Human Normal Immunoglobulin
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Multi-centre Open Study to Assess the Safety and Efficacy of Subgam®
Details : Human Normal Immunoglobulin is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Primary Immunodeficiency Diseases.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
September 23, 2014
Lead Product(s) : Human Normal Immunoglobulin
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
